相关实验视频

Updated: Jun 13, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

与乙型肝炎相关的肝癌治疗效果的因素分析

Shuai-Wei Liu^1,2, Yan Zhou^1,2, Xue Yan Feng^1,2

¹Department of Infectious Diseases, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China.

Journal of hepatocellular carcinoma

|June 11, 2025

概括

与乙型肝炎相关的肝癌的药物排泄珠跨导管动脉化学栓塞 (DEB-TACE) 表明预后取决于瘤因素和炎症. 识别这些标志物有助于个性化治疗,以获得更好的结果.

科学领域:

肝病学肝病学是一种肝病学.
在瘤学瘤学.
干预性放射学干预性放射学

背景情况:

肝细胞癌 (HCC) 是慢性乙型肝炎感染的主要并发症.
药物释放珠子透气管动脉化学栓塞 (DEB-TACE) 是不可切除的HCC的标准治疗方法.
由于多种影响因素,DEB-TACE患者的治疗结果各不相同.

研究的目的:

鉴定DEB-TACE治疗的与乙型肝炎相关的HCC患者的临床因素影响整体生存 (OS) 和无进展生存 (PFS).
为HCC管理提供个性化治疗策略的数据.
分析瘤特征,炎症标志物和生物化学参数对患者预后的影响.

主要方法:

对128名接受DEB-TACE的乙型肝炎相关HCC患者的回顾性分析.
评估临床特征,瘤标志物,炎症因素和血液生物化学参数.
统计分析包括Kaplan-Meier,Log等级测试和Cox回归来确定预后因素.

主要成果:

瘤大小,数量,血管入侵,肝外转移,BCLC/CNLC阶段和α-胎蛋白 (AFP) 显著影响了OS和PFS.
手术前的炎症标志物 (WBC,ANC,PCT,CRP) 和生化参数 (AST,TBIL,ALB) 与预后相关.
多变量分析确定了年龄,Child-Pugh得分,BCLC阶段,TBIL,ALB,CRP和AFP作为OS的独立预后因素.

结论:

瘤的临床特征和手术前的炎症因素对于预测乙型肝炎相关的HCC中DEB-TACE结果至关重要.
对这些标记物的全面评估可以指导个性化治疗规划.
更好地了解预后因素可以提高治疗疗效和患者存活率.

关键词:

债务资产债务资产与HBV相关的肝细胞癌.总体存活率总体存活率预后因素预后因素没有进展的生存率.

更多相关视频

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

相关概念视频

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...